Plain Language Summaries is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • How to
  • FAQs
  • Publications
  • Advisory Panel
    • Plain Language Advisors
    • Scientific Content Advisors
  • Supporters
  • Blog
  • About us
  • Contact Us

biosimilar

25th Feb 2026

ADACCESS trial results comparing GP2017 (adalimumab biosimilar) and reference adalimumab treatments for plaque psoriasis: a plain language summary

23rd May 2025

Plain language summary: Real-world outcomes of SDZ ETN (etanercept biosimilar) treatment for rheumatic diseases in the COMPACT study

17th Mar 2025

A plain language summary of the combined safety findings of adalimumab-adbm from the VOLTAIRE clinical trials in individuals with rheumatoid arthritis, Crohn’s disease, and chronic plaque psoriasis

1st Mar 2023

Plain language summary of the VOLTAIRE-CD study in people with moderate-to-severe active Crohn’s disease

Copyright © 2026 · Plain Language Summaries · Terms and conditions · Privacy policy · Cookie policy